Travere Therapeutics (TVTX) EPS (Weighted Average and Diluted): 2013-2024
Historic EPS (Weighted Average and Diluted) for Travere Therapeutics (TVTX) over the last 12 years, with Dec 2024 value amounting to -$4.08.
- Travere Therapeutics' EPS (Weighted Average and Diluted) rose 140.00% to $0.28 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.04, marking a year-over-year increase of 77.14%. This contributed to the annual value of -$4.08 for FY2024, which is 19.53% up from last year.
- Latest data reveals that Travere Therapeutics reported EPS (Weighted Average and Diluted) of -$4.08 as of FY2024, which was up 19.53% from -$5.07 recorded in FY2023.
- Travere Therapeutics' 5-year EPS (Weighted Average and Diluted) high stood at -$3.56 for FY2020, and its period low was -$5.20 during FY2022.
- Over the past 3 years, Travere Therapeutics' median EPS (Weighted Average and Diluted) value was -$5.07 (recorded in 2023), while the average stood at -$4.78.
- In the last 5 years, Travere Therapeutics' EPS (Weighted Average and Diluted) tumbled by 43.25% in 2022 and then increased by 19.53% in 2024.
- Over the past 5 years, Travere Therapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at -$3.56 in 2020, then fell by 1.97% to -$3.63 in 2021, then plummeted by 43.25% to -$5.20 in 2022, then climbed by 2.50% to -$5.07 in 2023, then grew by 19.53% to -$4.08 in 2024.